{"title":"卡介苗-谷氨酰胺疫苗保护效果的现状","authors":"P. Méndez-Samperio","doi":"10.29252/vacres.6.1.29","DOIUrl":null,"url":null,"abstract":"Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The current status of bacillus Calmette‐Guérin vaccine protective efficacy\",\"authors\":\"P. Méndez-Samperio\",\"doi\":\"10.29252/vacres.6.1.29\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.\",\"PeriodicalId\":52727,\"journal\":{\"name\":\"Vaccine Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29252/vacres.6.1.29\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29252/vacres.6.1.29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The current status of bacillus Calmette‐Guérin vaccine protective efficacy
Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
